Rhythm Pharmaceuticals highlights IMCIVREE launch progress in acquired hypothalamic obesity presentation

Reuters2026/09/08 22:22

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Rhythm Pharmaceuticals highlighted IMCIVREE’s U.S. launch for acquired hypothalamic obesity following FDA clearance on March 19, 2026.
Japan launch anticipated by year-end 2026; European country launches expected to begin in 2027 following European Commission authorization.
Early U.S. uptake: more than 400 patient start forms in the first 14 weeks; about 300 unique prescribers.
Cash, cash equivalents, short-term investments totaled USD 330.9 million as of June 30, 2026; 68.6 million common shares outstanding.
Pipeline milestones include a year-end 2026 start of a pivotal Phase 3 trial of oral bivamelagon in acquired hypothalamic obesity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Rhythm Pharmaceuticals highlights IMCIVREE launch progress in acquired hypothalamic obesity presentation

You may also like

Crypto prices